Drugs / Pharmorubicin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02547350 | Sep 2015 → Dec 2020 | renal pelvis/ureter urothelial carcinoma, urinary bladder cancer | Xuesong Li | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02338518 | Jan 2015 → May 2019 | gastric cancer | Jinling Hospital, China | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04061772 Background | Aug 2019 → Jul 2021 | peripheral T-cell lymphoma, not otherwise specified | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03892330 Comparator | Jun 2019 → Dec 2020 overdue | childhood kidney Wilms tumor | Shengjing Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pharmorubicin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04061772 ↗ |
| Route | Other | “pharmorubicin 30 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.” NCT02338518 ↗ |